Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.50 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992701 | 0.77 | HPRT1 (0.54) | HPRT1PNPALDH1A1 | |
| SCHEMBL24021919 | 0.76 | HPRT1 (0.47) | HPRT1PNPADORA3 | |
| SCHEMBL218668 | 0.76 | XDH (0.53) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL7396872 | 0.75 | HPRT1 (0.46) | HPRT1PNP | |
| SCHEMBL4560686 | 0.75 | LMNA (0.47) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL3060812 | 0.74 | HPRT1 (0.45) | HPRT1PNP | |
| SCHEMBL28415478 | 0.73 | ALDH1A1 (0.37) | HPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL8791177 | 0.72 | HPRT1 (0.51) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL21362204 | 0.72 | HPRT1 (0.51) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL13145301 | 0.72 | HPRT1 (0.51) | HPRT1PNPLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIV CINCINNATI (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIV CINCINNATI (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2014194250-A2 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIVERSITY OF CINCINNATI (US) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | DCTD, TYMS, CDA | HPRT1 140/4885PNP 36/4885LMNA 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.